clinical trial
[대역어] 임상시험
[용어속성] Term
[용어속성] Term
A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation
Article
[키워드] 95% confidence interval
adverse event
Adverse reaction
AEs
Analysis
analyzed
Arrhythmias
Atrioventricular block
authorization
calculate
cardiac
cardiac dysfunction
Cardiomyopathy
cardiovascular adverse events
clinical benefits
Clinical studies
clinical study
clinical trial
Complete
coronavirus disease
COVID-19
database
dataset
determine
diastolic
drug
dysfunction
Effectiveness
Efficacy
Ejection fraction
Emergency
EUA
FDA
feasible
food
HCQ
High dose
higher risk
highlight
Hospitalized
Hydroxychloroquine
investigated
Mitigation
non-randomized
Odds ratio
outcome
Patient
patients
performed
pharmacovigilance
pharmacovigilance analysis
Potential
predict
QT prolongation
Randomized
Reactions
receiving
reported
robust
Safety
subsequent
therapy
torsades de pointe
torsades de pointes
treatment regimen
ventricular
was used
widespread
with COVID-19
[DOI] 10.3390/jcm9061867 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/jcm9061867 PMC 바로가기 [Article Type] Article
The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series
Internal Medicine
[키워드] acute respiratory distress
Administered
China
Clinical course
clinical trial
coronavirus
coronavirus disease
COVID 19
COVID-19
COVID-19 patient
cytokine
D-dimer levels
effective
ferritin level
health emergency
Healthcare systems
Hydroxychloroquine
hypoxemic
Hypoxemic respiratory failure
IMPROVE
increase in
Infection
Inflammation
Inflammatory marker
inflammatory mediator
inhibitors
interleukin (il)-6
lactate dehydrogenase
medication
moderate
morbidity and mortality
Novel coronavirus
outbreak
oxygen saturation
Pathogenesis
pathophysiology
Pneumonia
Research
Respiratory failure
role
SARS-CoV-2
Sery
severe symptoms
syndrome
targeting
the disease
Tocilizumab
Treatment
World Health Organization
worsened
[DOI] 10.7759/cureus.8631 PMC 바로가기 [Article Type] Internal Medicine
[DOI] 10.7759/cureus.8631 PMC 바로가기 [Article Type] Internal Medicine
Should azithromycin be used to treat COVID-19? A rapid review
Research
[키워드] adverse event
Anti-bacterial agents
Anti-SARS-CoV-2 Activity
Azithromycin
Bacterial
clinical trial
clinical trials
Comparator group
conducted
COVID
COVID-19
drug
effective
Effectiveness
Evidence
for inclusion
General practice
Google
high risk
Hydroxychloroquine
in vitro
in vitro study
in vivo
include
Map
medRxiv
patients
patients with COVID-19
Primary Health Care
Result
SARS-CoV-2
Support
synergy
treat
treated
treating COVID-19
Treatment
treatments for COVID-19
Trial
viral clearance
while
[DOI] 10.3399/bjgpopen20X101094 PMC 바로가기 [Article Type] Research
[DOI] 10.3399/bjgpopen20X101094 PMC 바로가기 [Article Type] Research
A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam
Study Protocol
[키워드] 24 hours
Can
cause
caused
Chloroquine
city
clinical trial
control arm
Controlled trial
Coronaviruses
COVID
COVID-19
defined
detect
effective
evaluate
exclusion criteria
field
Ho Chi Minh
hospital
hospitalised
hypothesise
Infection
intervention arm
Loading dose
malaria
management
morbidity and mortality
multi
nine
Novel coronavirus
open label
outcomes
Parallel Arm
Patient
patients with COVID-19
people with COVID-19
pilot study
positive
Prevent
primary endpoint
randomised
randomised clinical trial
randomization
Randomized
randomized trial
recruit
Respiratory disease
resulting
RT-PCR
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 RNA
Standard of care
Swab
swabs
therapeutic
Tolerability
treat
Treatment
Trial
Vaccine
Vietnam
viral clearance
Viral load
viral replication
[DOI] 10.12688/wellcomeopenres.15936.1 PMC 바로가기 [Article Type] Study Protocol
[DOI] 10.12688/wellcomeopenres.15936.1 PMC 바로가기 [Article Type] Study Protocol
The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19) A protocol for systematic review and meta analysis
3800
[키워드] adverse events
Analysis
Anxiety
appears
CBM
China
Chinese
clinical
clinical trial
CNKI
coronavirus disease
COVID-19
COVID-19, protocol
database
death
Efficacy and safety
evaluate
Evidence
exceeded
Fang
Google
Government
Infrastructure
Jinhua Qinggan Granule
journal
Meta-analysis
Novel coronavirus
number of infected
ongoing trial
patients with COVID-19
peer-reviewed
platform
Primary outcome
promoted
protocol
registry
secondary outcome
submitted
Symptom
syndrome
systematic review
TCM
Treatment
VIP
was used
Web of Science
[DOI] 10.1097/MD.0000000000020531 PMC 바로가기 [Article Type] 3800
[DOI] 10.1097/MD.0000000000020531 PMC 바로가기 [Article Type] 3800
Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)
중증 COVID-19 환자를 치료하기 위한 동종 인간 치수 줄기세포의 안전성 및 효능 평가: 무작위 대조 시험(I/II상)을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
Acidic
Adenovirus
Admission
AIDS
Alanine
alanine aminotransferase
albumin
alkaline phosphatase
Allogeneic
allogeneic human dental pulp stem cells
amyloid
Analysis
anion gap
Arm ratio
aspartate
Aspartate aminotransferase
average
B lymphocyte
basophils
Before menopause
Bilirubin
blind
blinded
Block randomization method
Blood
blood cell
Blood cells
blood pressure
Blood routine
C-reactive protein
calcium
carbon dioxide
Care
CAST
caused
Cell
cell suspension
change
chest X-ray
Child Pugh score
chlorine
cholesterol
cholinesterase
CLARITY
clinical
Clinical improvement
clinical trial
coded
Coefficient of variation
color
commenced
comparator
computer
Concentration
Consent
consent form
Continuous renal replacement therapy
control group
control groups
COVID-19
COVID-19; randomised controlled trial; protocol; human dental pulp stem cells; dental stem cell banking
COVID-2019
creatine
creatine kinase
creatinine
criteria
crystal
Cytokines
cytomegalovirus
cytomegalovirus CMV-IgG
cytomegalovirus CMV-IgM
Definition
dental pulp
dental pulp stem cells
description
detect
Diastolic blood pressure
direct bilirubin
discharge
disease
dissemination
distress
distribution
DPSCs
ECMO
Efficacy
element
enrolled
eosinophil
eosinophils
epithelial cells
estimated glomerular filtration rate
Estrogen
examined
excluded
exclusion criteria
experimental group
fat globules
Female patients
female subject
filtration rate
Final
flow cytometry
follow-up period
fungi
fungus
Globulin
glomerular filtration rate
Glucose
GRADE
Grade 1
grade 3
Grade 5
granulocyte
HBcAb
HBeAb
HBeAg
HBsAb
HBsAg
hDPSCs
Health Organization
heart rate
hematocrit
Hemodialysis
hemoglobin
hepatitis B
hepatitis C
HFNC
high density lipoprotein
hospitalised patient
Hospitalised patients
Hospitalization
Hospitalized
human DPSC
human DPSCs
hypersensitive C-reactive protein
hypoxia
Identifier
IgA
IgG
IgM
Il -10
IL-1
IL-1 β
IL-2
IL-4
IL-6
immune
Immunoglobulin
Immunological testing
improvement
IMV
inclusion criteria
Infectious disease
Influenza
Influenza virus
informed consent form
injection
Injections
intensive care
intensive care unit
Intravenous injection
Invasive mechanical ventilation
investigator
investigators
ITN-γ
ketone
ketone bodies
Kidney function
Kidney function tests
Killer cell
Laboratory
laboratory examinations
Lactate
lactate dehydrogenase
lactating women
leukocyte
leukocyte enzymes
lipoprotein
lipoprotein A
lipoprotein cholesterol
low density lipoprotein
lung lesion
lung lesions
lymphocyte
Lymphocytes
Macrophage
Magnesium
Medical care
Menopause
Monocytes
mononuclear cell
mononuclear cells
nasal
nasal catheter
natural killer
natural killer cell
neutrophil
Neutrophils
nitrite
NIV
Non-invasive
non-invasive mechanical ventilation
non-squamous epithelial cell
non-squamous epithelial cells
nucleic acid
nucleic acid test
number
objective
observation
occult
occult blood
Other
Other condition
outcome
oxygen
oxygen saturation
parallel group
parasites
partial pressure
participant
Patient
penetration
performed
Peripheral blood
Peritoneal dialysis
phase
phenotype
phosphatase
phosphorus
Placebo
placebo-controlled
Platelet
Platelet count
platelet distribution width
Platelets
Potassium
prealbumin
pregnancy test
pregnant
pressure
Primary outcome
Protein
protocol
random
randomisation
randomization
Randomized
Randomized controlled trial
receive
receiving
recruitment
red blood cell
red blood cells
renal
renal insufficiency
renal replacement therapy
Renmin Hospital
replacement therapy
required
researcher
respiratory
respiratory distress
respiratory infection
respiratory rate
Safety
Saline
saline solution
Sample size
SARS-CoV-2
secondary
Secondary outcomes
serious COVID-19
serum
serum amyloid
severe liver condition
severe pneumonia
single-cell analyses
sodium
specific gravity
Standard deviation
status
stem cell
study period
Study protocol
sugar
syphilis
Systolic blood pressure
T lymphocyte
Th1 cytokine
Th1 cytokines
Th2 cytokine
Th2 cytokines
therapeutic effect
therapeutic effects
time
TNF-a
Total
total bilirubin
Total cholesterol
total protein
traits
Transferrin
treat
Treatment
treatment for COVID-19
triacylglycerol
Trial
triple blinded
TTCI
Tuberculosis
Twenty participant
Twenty participants
university
urea
uric acid
Urine
urobilinogen
Variation
Version
vital signs
Volume
website
White blood cells
with HIV
within 6 months
women
World Health Organization
Wuhan
γ-glutamyl transferase
[DOI] 10.1186/s13063-020-04380-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04380-5 PMC 바로가기 [Article Type] Letter
Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID ‐19
Concise Review
[키워드] accompanied
accumulated
acute respiratory distress
Allogeneic
ARDS
Asthma
Bacterial
bacterial pneumonia
chronic obstructive
clinical trial
Clinical use
COPD
COVID
COVID‐19
COVID‐19
curative
current
Cytokine storm
disease
Diseases
disorder
disorders
Effect
effective
Evidence
Gleaning
Idiopathic pulmonary fibrosis
immunomodulatory property
Influenza
lack
lung
lung disorders
mesenchymal stem cell
Mesenchymal stem cells
mortality rate
MSC
MSC therapy
MSCs
novel coronavirus disease
outcomes
pandemic
Perspective
preclinical data
pulmonary conditions
pulmonary disease
pulmonary injury
regenerative
reported
stem cell
Stem cell therapy
syndrome
therapeutic
therapeutic use
therapy
[DOI] 10.1002/sctm.20-0186 PMC 바로가기 [Article Type] Concise Review
[DOI] 10.1002/sctm.20-0186 PMC 바로가기 [Article Type] Concise Review
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
프로토타입 병원체 대비를 통한 SARS-CoV-2 mRNA 백신 개발
Article
[키워드] Betacoronavirus
breath
CD8 T cell
CD8 T cell responses
clinical trial
COVID-19
development
Efficacy
Evidence
evidence of
expressing
expression
Health crisis
immunogenicity
immunopathology
induce
lung
Lungs
mice
mRNA
mRNA vaccine
mRNA-1273
Mutation
neutralizing antibody
phase
Phase 2
prefusion
PROTECT
prototype
public health crisis
response
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 sequence
SARS-CoV-2 sequences
SARS-CoV-2 spike trimer
SARS-CoV-2 vaccine
Spike proteins
Structure
T cell
trajectory
triggered
[DOI] 10.1101/2020.06.11.145920 PMC 바로가기 [Article Type] Article
[DOI] 10.1101/2020.06.11.145920 PMC 바로가기 [Article Type] Article
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Article
[키워드] 105 patient
acute respiratory distress
Analysis
case sery
Clinical improvement
Clinical outcome
clinical trial
COVID-19
COVID-19 Inflammation Score
cytokine
Cytokines
detect
Efficacy
hyperinflammation
Inflammatory diseases
inhibitor
initiated
janus
Janus kinase
kinase
median
median cumulative dose
multicenter
multiorgan failure
overcome
Patient
Prevent
progression
proinflammatory cytokines
reduction
Rux
ruxolitinib
Safe
severe COVID-19
shown
stratified
subgroup of patient
sustained
syndrome
systemic hyperinflammation
Toxicity
Translational research
treated
treatment for COVID-19
was performed
[DOI] 10.1038/s41375-020-0891-0 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41375-020-0891-0 PMC 바로가기 [Article Type] Article